Podcasts about Igan

Iganädalases poliitilises vestlussaates "Räägime asjast" räägivad asjast EKRE juhtpoliitikud Martin ja Mart Helme, seekord on saate külaliseks Rain Epler.Esimese teemana võetakse ette peaminisiter Kristen Michali ja kaitseminister Hanno Pevkuri mõte saata eesti sõdurid Ukrainasse. Tegemist on Eesti jaoks väga ohtliku plaaniga, millega EKRE pole mitte mingil juhul nõus. Ei ühtki eesti poissi Ukrainasse!Saate teises osas liitub saatejuhtidega Riigikogu liige Rain Epler, kellega räägitakse Pürenee poolsaarel toimunud ulatuslikest elektrikatkestustest. On selge, et üleminek nn rohelisele energiale kukutab kokku energiasüsteemid ja toob kaasa tohutud lisakulud.Saate lõpetab ülevaade USA presidendi Donald Trumpi sajast võimul oldud päevast. Eesti peavoolumeedia seda ei kajasta või, kui võtabki midagi mainida, siis ikka valetades.

Uplizna gains new indication; Vanrafia approved for proteinuria in IgAN; Erzofri now available for schizophrenia; setmelanotide shows promise in hypothalamic obesity; GLP-1RAs may reduce dementia risk.  

Paul Williamson delivers four solid streaming options for Wednesday, including his stream of the day! He also goes over some recent injury news and some happenings across MLB. ***Stream of the Day Tracker*** SUBSCRIBE, Rate and Review on Apple and Spotify! Follow us on Twitter: @EthosFantasyBB Follow us on Bluesky: @ethosfantasymlb Join our Fantasy Sports Discord Server: https://discord.gg/jSwGWSHqaV

Iganädalases poliitilises jutusaates "Räägime asjast" räägivad asjast EKRE juhtpoliitikud Martin ja Mart Helme, seekord on stuudios ka huvitavad saatekülalised, kelleks on Kersti Kracht ja telefonitsi Kert Kingo.Tegemist on omamoodi juura-eriga, sest kommenteeritakse nii Kersti Krachti akui ka  Kert Kingo kohta käivaid kohtuotsuseid, mis tehti teatavaks samal päeval.Võetakse ette justiitssüsteem, kus üha enam näib, et prokuratuur ja organid tegelevad rohkem poliitika kui õigusemõistmisega.Kolmandaks teemaks on Donald Trump ja tema tariifid, milles on oma iva, aga mitte see, millest pajatab peavoolumeedia. 

In this episode, Ayesha spoke with Marshall Fordyce, MD, founder and CEO of Vera Therapeutics, a company focused on developing treatments for autoimmune diseases. Dr. Fordyce founded Vera in 2016 as an entrepreneur in residence at Kleiner Perkins Caufield and Byers, took the company public in 2021 and has advanced its lead molecule through a successful Phase II trial in IgA nephropathy. The company is on track to read out its Phase III results next quarter. Along the way, Dr. Fordyce has built a world class team of drug developers and raised over $1 billion in capital. Dr. Fordyce previously worked in clinical development leadership roles at Gilead Sciences in the 2010s, driving innovation in treatments for HIV and hepatitis. Dr. Fordyce received his BA from Harvard University and MD from Harvard Medical School, trained in Internal Medicine and served as Chief Resident at NYU Bellevue. Dr. Fordyce currently serves on the Board of Directors and as Treasurer of the Albert and Mary Lasker Foundation. Tune in to hear Dr. Fordyce discuss new innovations in therapies for autoimmune diseases like IgA nephropathy and the work he is leading at Vera Therapeutics. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

Iganädalases poliitilises vestlussaates "Räägime asjast" räägivad asjast EKRE juhtpoliitikud Martin ja Mart Helme, kes võtavad ette kolm lõppeva nädala kuumemat teemat.Kolmapäeval võttis Riigikogu vastu põhiseaduse muudatuse, mille kohaselt saavad edaspidi kohalike omavalitsuste valimisel valida vaid Eesti kodanikud. Eesti Konservatiivne Rahvaerakond saavutas täpselt seesuguse muudatuse, mida algusest peale nõudis. See on EKRE ja Eesti võit! Arutatakse ka, mida uus olukord juba tulevastel kohalike omavalitsuste valimistel kaasa toob ning kuidas see mõjutab erinevate parteide toetust.Teise teemana räägivad Mart ja Martin Helme Riigikogu juhatuse valimistest ja selle taustaks olnud intriigidest. Riigikogu teise aseesimehena jätkab EKRE saadik Arvo Aller. Opositsioon on pannud seljad kokku ning jätnud sotsid poliitilise tulemüüri taha.Saate viimases osas tõstatub julgeolekuolukord: maailmas on kokku vaid kolm riiki, mis on valmis viima oma väed Ukrainasse. Üks neist on Kristen Michali juhtimisel "impeerium" Eesti. Kipume sõtta ilma, et meil oleks võimekus sõdida.

Iganädalases poliitilises saates "Räägime asjast" keskenduvad EKRE juhtpoliitikud Martin ja Mart Helme kolmele teemale. Saate esimeses osas räägivad saatejuhid Eestis lahvatanud valitsuskriisist, mille on käivitanud Reformierakond. Kas oma tahtmise saamiseks pressitakse sotsidelt välja või ongi plaan oma populaarsuse parandamiseks valitsust remontida? Pole kahtlust, et Isamaa läheb valitsusse ükskõik kellega, ükskõik millal. Teises osas tuleb jutuks EKRE volikogu avaldus, mis keskendus energiapoliitikale. Tuulikud, päikesepaneelid ja gaasijaamad tuleb prügikasti visata, põlevkivielekter odavaks teha ja alustada tuumajaama arendamisega.Viimane teema on pühendatud välispoliitikale ning arutluse all on Euroopa Liit. Ühtäkki on saanud Euroopa Liidust kui rahuprojektist sõjaprojekt. Välja töötatakse kava, mis võtab ära meie raha ja kontrolli kaitsejõudude üle, aga kaitstumaks me sellest ei saa.

Iganädalases poliitilises vestlussaates "Räägime asjast" räägivad asjast Eesti Konservatiivse Rahvaerakonna juhtpoliitikud Martin ja Mart Helme.Saate esimeses osas kommenteeritakse USA süvariigi varirahakoti ehk USAIDi tegemiste paljastusi ja nende seotust Eestiga. Ameerika maksumaksja on ainuüksi Eestis rahastanud sadade miljonite eest globalistlikke äärmusideoloogiaid. Maksnud kinni nö ajakirjanikke, eksperte ja kodanikuaktiviste.Saate teise teemana käsitletakse veel kord tuulikute vastast kampaaniat. Arutletakse selle üle, miks ikkagi on valitsusel nõnda kiire miljardite tuulde loopimisega.Kolmanda teemana kajastavad saatejuhid valimisi Saksamaal ja AFD võimalusi sealset poliitikat mõjutada.

Iganädalases konservatiivses vestlussaates "Vaba sõna" räägivad Riigikogu EKRE fraktsiooni liikmed Anti ja Evelin Poolamets aktuaalsetel teemadel poliitikas. Seekord on juttu ikka tuuleparkide teemal Vinni valla näitel, kus on läundu väga pingeliseks. Ei saa rääkimata ka sellest, kuidas meie haridusminister Kristina Kallas on veendunud, et olemas on 20 ja enamgi sugu.EKRE suutis Vinni vallavolikogus tõrjuda tuulikuärimeeste rünnaku, kuid Isamaa saadikud polnud sellega nõus ning esitasid hoopis vallavolikogu esimehele Evelin Poolametsale umbusalduse.“Vaba sõna” on eetris laupäeviti kell 12 Tre-raadios, sagedustel 97,0 Lääne-Virumaal ja osaliselt Ida-Virumaal. Saade on järelkuulatav Uutes Uudistes ning aadressil treraadio.ee.

Guest: Donald Kohan, MD, PhD Increased formation of renal endothelin one is associated with renal injury.1 In several studies, activation of the ETA receptor has been shown to contribute to IgA nephropathy (IgAN) progression, and markers of endothelin system activity are elevated in patients with the disease.2,3-5 Join Dr Donald Kohan as he dives into the latest research on this connection, which could provide insight into new tailored therapy approaches for IgAN patients. Dr Kohan is a nephrologist at University of Utah Health in Salt Lake City. References: Kohan DE, Barton M. Kidney Int. 2014;86(5):896-904. doi:10.1038/ki.2014.143 Kohan DE et al. Kid Int Rep. 2023;8(11):2198-2210. doi:10.1016/j.ekir.2023.07.023 Lehrke I et al. J Am Soc Nephrol. 2001;12:2321-2329. doi.org/10.1681/ASN.v12112321 Zanatta CM et al. Ren Fail. 2012;34(3):308-315. doi:10.3109/0886022X.2011.647301 Tycova I et al. Physiol Res. 2018;67:93-105. doi.org/10.33549/physiolres.933670 FA-11319389 12/24

Our experts will take you through patient cases and the latest clinical data for potentially game-changing therapies for patients with IgA nephropathy (IgAN). Credit available for this activity expires: 01/03/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/emerging-iga-nephropathy-advances-digging-deep-b-cell-2024a1000pfe?ecd=bdc_podcast_libsyn_mscpedu

Please visit answersincme.com/NRR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in the treatment of IgA nephropathy (IgAN) discusses novel therapeutic approaches in the management of IgAN. Upon completion of this activity, participants should be better able to: Outline the unmet needs in patients with IgAN; Discuss the clinical implications of new and emerging targeted therapies in IgAN; and Identify patient-centered strategies for long-term management of IgAN.

CME credits: 0.25 Valid until: 30-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/unmasking-igan-from-suspicion-to-timely-diagnosis/26629/ Because renal biopsy is required for diagnosis, providers must be able to identify the histopathological characteristics of IgA nephropathy and implement a systemic diagnostic approach. In addition, the mechanisms of action of some IgAN therapies may offer advantages over others in targeting specific pathways in disease pathophysiology. Join the experts for an exploration of these important clinical topics using a patient case study.=

CME credits: 0.25 Valid until: 13-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/advances-in-igan-care-from-kidney-week/26628/ In this review of clinical trial results, experts cover the latest data in IgA nephropathy and discuss how their application can improve outcomes for your patients. Studies presented include SPARTAN, SPARTACUS, and the PROTECT open-label extension. Throughout this conversation, faculty also consider the anticipated updates to the KDIGO clinical guidelines. =

While housing markets play a significant role in economies, new research shows houses across 40 countries are less affordable than at any time since the 2008 financial crisis. IMF economist Deniz Igan helped develop the Housing Affordability Index. In this podcast, she says the pandemic triggered an unusual sequence of events that housing markets around the world are still struggling to correct.  Transcript: https://bit.ly/49AeK0N Read the article in Finance and Development: IMF.org/fandd

CME credits: 0.25 Valid until: 21-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-outcomes-in-patients-with-igan-novel-therapies-and-evolving-guidelines/26627/ Given that IgA nephropathy is a leading cause of kidney failure, early diagnosis and treatment are essential. In the landscape of the many evolving treatment guidelines, how can nephrologists apply emerging evidence and utilize newer therapies to achieve proteinuria remission and maintain eGFR to improve the outcomes of their patients? Hear the experts answer these questions by reviewing a real-world clinical patient case.=

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Candid, a startup, is investing $370 million to prove the worth of bispecifics in autoimmune diseases. Summit's lung cancer drug has shown significant benefits over Keytruda, a popular immunotherapy drug. Relay's breast cancer drug also showed promise in early trials. Biotech IPOs are crucial in the industry, and their performance is being closely monitored. Early study data on Terns, a potential contender in the obesity drug market, is also discussed.Summit Therapeutics has declared victory over Keytruda in advanced non-small cell lung cancer, with their drug Ivonescimab showing a 49% higher effectiveness in reducing disease progression or death in a late-stage study. GSK is set to approach the FDA with positive Phase III data for a long-acting asthma medication. Terns Pharmaceuticals' investigational GLP-1 pill has shown promising weight loss results. Sino Biological has launched a new center for bioprocessing, and various pharmaceutical companies are making advancements in their pipelines. The FDA tracker highlights Travere's full approval for an IgAN drug.The challenges faced in the cell and gene therapy industry as it grows in popularity among investors and innovators are discussed. Shortages of brand-name diabetes and obesity medications from Novo Nordisk and Eli Lilly, such as Ozempic and Mounjaro, are due to high demand. Efforts are being made to ramp up manufacturing and develop new medications. Lilly recently made a billion-dollar deal with Haya Therapeutics to develop genetic obesity medications. The revival of drugs for Huntington's disease after initial trial failures is mentioned. Challenges in turning new drugs into successful assets even after FDA approval are highlighted, along with a poll on which presidential candidate would support policies favorable to the pharma industry. Information on staying compliant with the EU GMP Annex 1 revision is also provided.

In this CCO Nephrology podcast episode, hear from nephrologists Pietro Canetta, MD, MS, and Andy Bomback, MD, PhD, experts in clinical management and research on glomerular diseases as they discuss key updates in managing IgAN. Faculty highlight the importance of a comprehensive supportive care regimen to protect patients' kidneys and prevent progression of disease. In addition, they review the merits and place in therapy of novel and emerging therapies.  Topics include:Supportive care as the foundation of IgAN managementPlace in therapy for new and emerging agentsTargeted-release formulation of budesonideEndothelin receptor antagonists (eg, sparsentan)Factor B inhibitors (eg, iptacopan)The role of clinical trial involvementLearn more about IgA nephropathy with educational activities and resources here:  CME-certified text module with animated pathophysiology video and patient voice audio clipClinicalThought commentariesResources on IgAN from the American Kidney Fund

Recent advances in our understanding of immunoglobulin A (IgA) nephropathy (IgAN) have led to an abundance of research into new therapies; our experts will guide you through it all. Credit available for this activity expires: 8/29/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1001534?ecd=bdc_podcast_libsyn_mscpedu

Are your patients' kidneys fighting a silent battle? Our experts give insight on earlier detection of IgAN and react to a real patient's experience. Credit available for this activity expires: 8/23/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1001513?ecd=bdc_podcast_libsyn_mscpedu

Jai Radhakrishnan, MD, MS, Getting Up to Speed in IgAN: An Expert-Led Rapid-Fire Journal Club Series

Jai Radhakrishnan, MD, MS, Getting Up to Speed in IgAN: An Expert-Led Rapid-Fire Journal Club Series

Jai Radhakrishnan, MD, MS, Getting Up to Speed in IgAN: An Expert-Led Rapid-Fire Journal Club Series

Jai Radhakrishnan, MD, MS, Getting Up to Speed in IgAN: An Expert-Led Rapid-Fire Journal Club Series

For this episode of the Global Kidney Care Podcast, Jonathan Barratt, MD, MSc, PhD is Professor of Renal Medicine, Department of Cardiovascular Sciences at the University of Leicester and Richard Lafayette, MD, FACP is a Nephrologist and Professor of Medicine at the Division of Nephrology Department of Medicine, Stanford University discuss the changing landscape in IgAN and disease modification approaches. This podcast is sponsored by Vera Therapeutics 

Dive into the fascinating world of immunoglobulin A nephropathy (IgAN), the most common form of primary glomerulonephritis worldwide. Credit available for this activity expires: 7/16/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1001351?ecd=bdc_podcast_libsyn_mscpedu

In this CCO Nephrology podcast episode, hear from Kelly Chen, a nephrology nurse practitioner and patient living with IgA nephropathy, as she discusses her experiences with Dr Pietro Canetta, Associate Professor of Medicine at Columbia University and expert in glomerular diseases. Episode outline: Seeking and obtaining an IgAN diagnosis Patient self-advocacy Individualizing IgAN treatment plansClinical trial involvement Burdens of IgAN: physical, emotional, social, and beyondTo learn more about IgA nephropathy, find more educational activities and resources with the links below: CME-certified text module with animated pathophysiology video and patient voice audio clipsClinicalThought commentaries Resources on IgAN from the American Kidney Fund 

The Filtrate:Joel TopfJosh WaitzmanWith Special Guest:Brad Rovin (@BradRovin) Chief of nephrology at The Ohio State University Wexner Medical Center, one of the authors of the Nefigard trial. Koyal Jain (@koyaljainMD) Program director of the GN Fellowship at University of North CarolinaRoger Rodby (@NephRodby) Associate program director of the Rush University Nephrology FellowshipEditor Sophia AmbrusoShow NotesThe manuscript (The Lancet | PubMed | NephJC)The Results of Part A (Kidney Int | PubMed)Edmund (Ed) Louis memorium by Steve Korbet in KISteve Korbet Do not miss this tweet TESTING Freely Filtered #48 with Sean BarbourIptapocan at the World Congress of Nephrology: WCN24-1506 Efficacy And Safety Of Iptacopan In Patients With IgA Nephropathy: Interim Results From The Phase 3 APPLAUSE-IgAN StudyFDA and mandatory post-marketing studies. What happens when the study is negative (or not completed) (UNDARK)Who should treat lupus nephritis: rheumatologists or nephrologists? (Nature Reviews Nephrology)Protein and albumin-to-creatinine ratios in random urines accurately predict 24 h protein and albumin loss in patients with kidney disease (PubMed)MEST Scores in NephJC Risk scores in IgAN in NephJCRepeat renal biopsy improves the Oxford classification-based prediction of immunoglobulin A nephropathy outcome (NDT)Tarpeyo pills 4 mg. Four pills once a day. (WellRx has a picture of the pills)IgA nephropathy in African Americans: uncommon but possible (PubMed Central)Aberrantly Glycosylated IgA1 in IgA Nephropathy: What We Know and What We Don't Know (PubMed Central)Effectiveness of Mycophenolate Mofetil Among Patients With Progressive IgA Nephropathy (JAMA Network Open)Tubular Secretions Joel: Constellation on Apple TV (Wikipedia). Not good. Dune audio books are excellent. (Audible)Josh: Podcasts about donating a kidneyOne Is Enough Podcast (National Kidney Registry)Donor Diaries (National Kidney Donation Organization)Roger Iceland (Wikipedia)Koyal India (Wikipedia)Brad Fishing in Dubai

CME credits: 1.00 Valid until: 12-11-2024 Claim your CME credit at https://reachmd.com/programs/cme/experts-on-the-ground-new-data-and-practical-clinical-integration-of-therapies-approved-for-igan/24046/ Expert Nephrologist Pietro Canetta, MD, MS, gives an overview of top abstracts from Kidney Week 2023 and new therapies for IgAN.=

CME credits: 0.25 Valid until: 12-11-2024 Claim your CME credit at https://reachmd.com/programs/cme/experts-on-the-ground-data-updates-on-emerging-therapies-for-igan/24045/ Expert Nephrologist Richard Lafayette, MD, FACP, gives an overview of top abstracts from Kidney Week 2023 and updates on emerging therapies for IgAN.=

Host: Richard Lafayette, MD, FACP Expert Nephrologist Richard Lafayette, MD, FACP, gives an overview of top abstracts from Kidney Week 2023 and updates on emerging therapies for IgAN.

Host: Richard Lafayette, MD, FACP Expert Nephrologist Richard Lafayette, MD, FACP, gives an overview of top abstracts from Kidney Week 2023 and updates on emerging therapies for IgAN.

For the AMA Style cheat sheet learnamastyle.com See the full write ups for today's episode at nascentmc.com/podcast Here are the highlights:  Test for Risk of Opioid Addiction:The FDA has approved AvertD by SOLVD Health, a test for assessing opioid addiction risk in individuals over 18, using genetic variants to evaluate addiction risk before prescribing oral opioids for acute pain; however, it's met with skepticism and not intended for chronic pain patients. https://www.cnn.com/2023/12/20/health/opioid-use-disorder-test-avertd/index.html https://avertdtest.com/  Filsuvez for Junctional Epidermolysis Bullosa:Filsuvez, a birch triterpenes topical gel, received FDA approval for treating Junctional and Dystrophic Epidermolysis Bullosa (JEB/DEB) in individuals aged 6 months and older, marking the first FDA-approved therapy for JEB's partial thickness wounds and a significant advancement in managing this debilitating skin disorder.https://resources.chiesiusa.com/Filsuvez/FILSUVEZ_PI.pdf Budesonide for IgA Nephropathy:Budesonide (Tarpeyo) received full FDA approval for reducing kidney function loss in adults with IgA nephropathy (IgAN), targeting specific antibodies implicated in IgAN based on phase 3 NefIgArd clinical trial data, marking the first FDA approval for IgAN treatment based on kidney function measures. https://www.tarpeyo.com/prescribinginformation.pdf Eplontersen for hATTR Polyneuropathy:Eplontersen (Wainua) was approved by the FDA for treating polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis (hATTR-PN), based on the NEURO-TTRansform Phase III trial, and is the only hATTR-PN treatment that can be self-administered via an auto-injector. https://pubmed.ncbi.nlm.nih.gov/37768671/ https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217388s000lbl.pdf NRX-101 for Complicated UTI:The FDA cleared an Investigational New Drug application for NRX-101, a D-cycloserine and lurasidone blend developed by NRx Pharmaceuticals for treating complicated urinary tract infections, with a pending request for Qualified Infectious Disease Product designation. https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-announces-fda-clearance-of-its-investigational-new-drug-ind-application-for-nrx-101-in-the-treatment-of-complicated-urinary-tract-infections-302017523.html?utm_source=pocket_saves Gefapixant for Chronic Cough:Merck's gefapixant, a selective antagonist of P2X3 receptors for treating chronic cough, was rejected by the FDA for the second time due to insufficient evidence of effectiveness in treating refractory or unexplained chronic cough in adults. https://www.businesswire.com/news/home/20231220302305/en/Merck-Provides-U.S.-Regulatory-Update-on-Gefapixant V116 for Invasive Pneumococcal Disease:Merck's V116, a 21-valent pneumococcal conjugate vaccine, was accepted by the FDA for priority review to prevent invasive pneumococcal disease in adults, based on STRIDE-3 Phase 3 trial data, with a target action date set for June 17, 2024. https://www.merck.com/news/fda-grants-priority-review-to-mercks-new-biologics-license-application-for-v116-an-investigational-21-valent-pneumococcal-conjugate-vaccine-specifically-designed-to-protect-adults Sotorasib in NSCLC:Lumakras (sotorasib), already under accelerated approval for KRASG12C-mutated non-small cell lung cancer (NSCLC), faces uncertainty for full FDA approval after an advisory committee voted against it, though it will remain available for clinical use.https://www.onclive.com/view/codebreak-200-sotorasib-in-second-line-kras-g12c-mutated-nsclc nascentmc.comlearnAMAstyle.com

Max Igan returns to the program to discuss Gaza and the Israeli onslaught that is ongoing. We discuss the strange, some say impossible, incompetency of the Israeli government on October 7th to stop the brutal assault of innocent Israelis followed by the total destruction of Gaza (not Hamas) and mass murder/genocide of tens of thousands of innocent Palestinians. This topic is personal to Igan who has many friends who lived in the Gaza strip who are now dead, missing or without a home. You can learn more and follow Max Igan on all his social media channels at https://thecrowhouse.com/This show is part of the Spreaker Prime Network, if you are interested in advertising on this podcast, contact us at https://www.spreaker.com/show/4656375/advertisement

After attending ASN Kidney Week, Bluestar Principal Jeff Fineberg sits down with Dr. Pietro Canetta to talk all things IgA nephropathy (IgAN). After Dr. Canetta provides a brief summary of his IgAN lecture at Kidney Week, Emerging Therapeutic Options in IgA Nephropathy, the two discuss the Filspari (sparsentan) data presented from both the PROTECT study, in IgAN, the DUPLEX study, in FSGS. From there, Dr. Canetta opines on the value of surrogate endpoints in predicting the three D's of CKD: death, dialysis, and doubling of serum creatinine (SCr). Dr. Canetta briefly discusses Novartis' press release announcing the positive Phase II data with atrasentan, another ETA RA, before the conversation shifts to other drug classes and therapeutic targets, including SGLT2 inhibitors, and B-cell activation (i.e., APRIL/BAFF). Finally, Jeff asks Dr. Canetta about whether the recent advancements in IgAN are generalizable to other glomerular diseases, and what might be the determinants of this. Jump to specific topics in the conversation: 00:00 Recap + guest intro/bio + Kidney Week lecture summary 05:05 Filspari (sparsentan) trial results from PROTECT (IgAN) and DUPLEX (FSGS) 12:25 Value of surrogate endpoints in predicting three D's - death, dialysis, and doubling of SCr - in glomerular disease 19:55 Atrasentan press release 23:05 The "four-hit" hypothesis of IgAN pathogenesis and SGLT2i 26:10 B-cell activation (APRIL/BAFF) as a therapeutic approach in IgAN 31:55 Generalizability (and lack thereof) of therapeutic approaches to other glomerular diseases 37:25 Where to learn more Helpful links: PROTECT Study (Filspari/sparsentan in IgAN) DUPLEX Study (Filspari/sparsentan in FSGS) Novartis press release (atrasentan in IgAN) ENVISION Study (sibeprenlimab in IgAN) Columbia Glomerular Center For more information about Bluestar BioAdvisors, please visit our website.

Max Igan returns to the program to discuss Gaza and the Israeli onslaught that is ongoing. We discuss the strange, some say impossible, incompetency of the Israeli government on October 7th to stop the brutal assault of innocent Israelis followed by the total destruction of Gaza (not Hamas) and mass murder/genocide of tens of thousands of innocent Palestinians. This topic is personal to Igan who has many friends who lived in the Gaza strip who are now dead, missing or without a home. You can learn more and follow Max Igan on all his social media channels at https://thecrowhouse.com/   Mentioned in the show: Learn more how you can convert your IRA or buy precious metals by emailing info@MilesFranklin.com - tell them ‘Sarah sent me” and get the best service and prices in the country. Find the ultimate list of Prepper and Unique Christmas gifts at https://sarahwestall.com/unique-christmas-gifts/ Help rebuild America and your independence - learn more at https://FreedomBuyingClub.com   Consider subscribing: Follow on my Substack at SarahWestall.Substack.com Follow on Twitter at https://twitter.com/sarah_westall See Important Proven Solutions to Keep Your from getting sick even if you had the mRNA Shot - Dr. Nieusma MUSIC CREDITS: “In Epic World” by Valentina Gribanova, licensed for broad internet media use, including video and audio       See video on Bastyon | Bitchute | Rumble | Odysee | Youtube | Freedom.Social   Max Igan Biography Max Igan is a teacher, metaphysical explorer, researcher, truth seeker, radio host, film-maker and one of the leaders of global awakening movement. As a documentary film maker, his films have reached millions of people world wide: “Transformation”, “The Calling”, and “The Awakening”. You can learn more about Max Igan or follow his work at https://thecrowhouse.com/        

In the first ever Biotech Matters podcast episode, Principal Jeff Fineberg, PhD, sits down with nephrologist Beatrice Goilav, MD, to talk all things Kidney Week. Dr. Goilav offers her thoughts on an ideal day-by-day itinerary, as well as her hopes for what will be presented at a variety of sessions, including drug trials in IgAN, and new studies of SGLT2 inhibitors. She also offers her perspective on the potential for complement inhibitors in glomerular diseases, and which of these drugs in development she is most interested in. Finally, she makes some recommendations on poster abstracts to visit in the exhibit hall. For more information about Bluestar BioAdvisors, please visit our website. Dr. Goilav hangs out on X (formerly known as Twitter) @BGoilav. Her DM is open to episode listeners with follow-on questions.

Did you know that, if left untreated, between 30% and 50% and up to 30% of patients with C3G and IgAN, respectively, will progress to end-stage kidney disease in 10 years?    Credit available for this activity expires: 5/30/2024 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/992405?ecd=bdc_podcast_libsyn_mscpedu

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Pietro A. Canetta, MD IgA nephropathy has a few aspects to it that make it challenging to develop medications, particularly, focused medications. So what are the challenges or limitations associated with the therapies? Join Dr. Charles Turck as he discusses this in-depth with Dr. Pietro Canetta, Associate Professor of Medicine at Columbia University Irving Medical Center. Dr. Canetta did not receive compensation for this interview.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Pietro A. Canetta, MD The available treatment options and even the current guidelines for the management of IgA nephropathy (IgAN) come with several limitations. Fortunately, new therapies are on the horizon that can help us address those challenges and slow disease progression in IgAN. Here with Dr. Charles Turck to discuss limitations and advances in the IgAN treatment landscape is Dr. Pietro Canetta, Associate Professor of Medicine at Columbia University Medical Center in New York.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Rajeev Raghavan, MD, M.Ed, FASN There are several key markers of disease progression in IgA nephropathy (IgAN) that we should be aware of, and the biochemical pathways involving endothelin-1 (ET-1) and angiotensin II (Ang II) play an important role in driving that progression. Joining Dr. Charles Turck to shed light on these two pathways and how our knowledge of ET-1 and Ang II may impact the treatment landscape is Dr. Rajeev Raghavan, Program Director for HCA Kingwood Internal Medicine in Texas.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Gates B. Colbert, MD, FASN Preserving kidney function in our patients with IgA nephropathy (IgAN) is absolutely critical as it reduces the burden of disease our patients face, but there's still room for improvement when it comes to proactively preventing kidney damage. So how can we optimize our approach to reduce that burden and preserve kidney function? Joining Dr. Charles Turck to share essential strategies is Dr. Gates Colbert, Assistant Clinical Professor at Texas A&M College of Medicine.

To receive up to 1.0 CME/CE credit please complete the evaluation and request form here:  https://www.ceconcepts.com/igan-ee-podcastThis activity will take learners on a deep dive into the pathophysiology of proteinuric glomerular disease, with an incisive focus on IgA nephropathy (IgAN). Expert faculty will review the totality of emerging evidence for novel therapeutics in IgAN, including an appraisal of consensus guidelines and regulatory updates. Finally, the session will conclude with a case-based segment wherein attendees will get to apply the principles they've learned to real-world clinical scenarios.Supported through an independent educational grant from Travere.

Guest: Gates B. Colbert, MD, FASN Although immunosuppressive therapy has been the backbone of IgA nephropathy (IgAN) treatment, this type of approach comes with several challenges. Here to share how non-immunosuppressive treatments could help revolutionize the IgAN treatment landscape is Dr. Gates B. Colbert, Assistant Clinical Professor at Texas A&M College of Medicine.

Guideline-orientated management of immunoglobulin A nephropathy (IgAN) includes enrolling patients who remain proteinuric despite optimized standard of care in clinical trials. Credit available for this activity expires: 3/22/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/989932?ecd=bdc_podcast_libsyn_mscpedu

Did you know that 25 to 30 percent of patients with immunoglobulin A nephropathy (IgAN) will progress to end-stage kidney disease within 20 to 25 years of presentation?  Credit available for this activity expires: 1/10/2024 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/986542?src=mkm_podcast_addon_986542

IgAN and Chronic Kidney Disease Our Special Guests will be Chronic Illness Warrior & Advocate Judy Akin and IgAn & Dialysis Warrior Ambreanna Joyce! Just a few days ago was the first ever IgAn Nephropathy Awareness Day! Our goal is to raise awareness for IgAn and for their story to be heard, so join us as we ask and answer the question “What is IgAn?” For more information on IgAn visit here: https://igan.org/iganday/ Watch our interview here: https://youtube.com/c/HopewithJonathan For more information on Hope with Jonathan: https://www.hopewithjonathan.com/ Follow Judy @ https://vm.tiktok.com/ZTdGDgL3W/ https://instagram.com/judy.sjourneyhawaii?igshid=YmMyMTA2M2Y= Follow Ambreanna @ https://vm.tiktok.com/ZTdGDxkDS/ https://instagram.com/ambrywiththebadbeans?igshid=YmMyMTA2M2Y= #igan #iganephropathy #chronickidneydisease

In 2021, a work group of international experts published an update to the 2012 iteration of this guideline. To do so they reviewed the latest evidence through a systematic literature review, with the aim of providing a useful resource for clinicians caring for individuals with glomerular disease through actionable recommendations. In this episode we speak to Professor Jürgen Floege, co-chair of the work group, to hear his insights on the key takeaways, and the clinical data that has emerged since the guideline update was made. By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at nephrology.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.  References available here Disclosures: Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity. The content for this series was developed independently of the ineligible companies. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors.  This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.  Discussion of Off-Label, Investigational or Experimental Drug Use: Corticosteroids are mentioned in the context of the treatment of IgA nephropathy and reducing kidney function decline or failure. Funding: This independent educational activity is supported by an educational grant from Travere Therapeutics. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Travere Therapeutics has had no influence on the content of this education.

Long time super researcher Max Igan as we dive into who the globalists are and what they want.

Join a King Hero interview with legend in truth media, Max Igan, the host of The Crowhouse! Live July 29th at 1:00 PM CDT. In this interview we're going to cover a variety of subjects he's dove deep into including the falsification of history and our timelines, his take on the controversial germ theory and Flat Earth, why he became exiled from his home in Australia (and how he's coped), what he sees is the greatest hope for humanity now in these times he predicted accurately would come, and why he thinks losing everything can be the greatest gift. In his own words here's a bunch about Max from his website www.thecrowhouse.com: My real given name will remain anonymous and my second name is Maxwell. My last name will also remain anonymous. I live in Queensland, Australia and at the time of writing this essay, it is June 2007 and I am 49 years old. The pen-name Max Igan that I have become known by is a combination of my middle name and my sons' middle name. As a matter of interest, Igan is the original Irish spelling of the name Ian, and no, I do not have any Irish roots, we just liked the name. :) I decided upon the name Max Igan as my pen-name & internet identity as a tribute to my son and as a dedication to him. Any and all work I have done on the internet I have done mainly for him, first and foremost. I have always had a strong love for art and music and spent many hours constructing drawings I would give away during my teenage years and a few pencil a pen drawings that I kept, some of which are displayed on this site. I began messing around in Photoshop, Bryce and a few other 3D programs in my spare time about 3 years ago and most of the art found on this site is a result of those ongoing efforts. He quotes Martin Luther King: "The Ultimate measure of a man is not where he stands in moments of comfort and convenience, but where he stands at times of challenge and controversy... Cowardice asks the question – Is it safe? Expedience asks the question – Is it Politic? Vanity asks the question – Is it popular? But Conscience asks the question – Is it right? And there comes a time when a man must take a position that is neither safe, nor politic, nor popular, but one must take it because it is RIGHT!” . Most of my time these days is spent on my radio show and video presentations, research into Government Corruption and Ancient History, working on my next book and artwork when I can find the time." --- Send in a voice message: https://anchor.fm/beth-martens/message